Pathology is intertwined with Immunohistochemistry and Carcinoma in his research. Giovanni Tallini integrates Immunohistochemistry and Pathology in his studies. In his work, Giovanni Tallini performs multidisciplinary research in Gene and Gene expression. Genetics is often connected to Karyotype in his work. In his papers, he integrates diverse fields, such as Karyotype and Chromosome. Giovanni Tallini performs multidisciplinary study in the fields of Chromosome and Genetics via his papers. Giovanni Tallini performs integrative Thyroid and Papillary thyroid cancer research in his work. Papillary thyroid cancer and Thyroid cancer are two areas of study in which he engages in interdisciplinary work. His research combines Endocrinology and Thyroid cancer.
His Pathology study typically links adjacent topics like Immunohistochemistry and Carcinoma. Giovanni Tallini merges many fields, such as Immunohistochemistry and Pathology, in his writings. Carcinoma and Internal medicine are frequently intertwined in his study. Internal medicine is frequently linked to Thyroid carcinoma in his study. Mutation and Chromosome are the subject areas of his Gene study. In his research, Giovanni Tallini performs multidisciplinary study on Mutation and Genetics. Giovanni Tallini conducts interdisciplinary study in the fields of Genetics and Chromosome through his works. Thyroid carcinoma and Thyroid cancer are the subject areas of his Thyroid study. With his scientific publications, his incorporates both Cancer research and Cancer.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer
Mingzhao Xing;William H. Westra;Ralph P. Tufano;Yoram Cohen.
The Journal of Clinical Endocrinology and Metabolism (2005)
MGMT Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients
Alba A. Brandes;Enrico Franceschi;Alicia Tosoni;Valeria Blatt.
Journal of Clinical Oncology (2008)
RAS Point Mutations and PAX8-PPARγ Rearrangement in Thyroid Tumors: Evidence for Distinct Molecular Pathways in Thyroid Follicular Carcinoma
Marina N. Nikiforova;Roy A. Lynch;Paul W. Biddinger;Erik K. Alexander.
The Journal of Clinical Endocrinology and Metabolism (2003)
Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity.
Jeffrey Liu;Bhuvanesh Singh;Giovanni Tallini;Diane L. Carlson.
Association Between BRAF V600E Mutation and Recurrence of Papillary Thyroid Cancer
Mingzhao Xing;Ali S. Alzahrani;Kathryn A. Carson;Young Kee Shong.
Journal of Clinical Oncology (2015)
Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases.
E. Salloum;Dennis Cooper;G. Howe;J. Lacy.
Journal of Clinical Oncology (1996)
Specific microRNAs are downregulated in human thyroid anaplastic carcinomas.
R. Visone;P. Pallante;A. Vecchione;R. Cirombella.
Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer.
Peng Hou;Dingxie Liu;Yuan Shan;Shuiying Hu.
Clinical Cancer Research (2007)
Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma.
Ginesa Garcia-Rostan;Giovanni Tallini;Agustin Herrero;Thomas G. D’Aquila.
Cancer Research (1999)
RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes.
Giovanni Tallini;Massimo Santoro;Mary Helie;Francesca Carlomagno.
Clinical Cancer Research (1998)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: